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Adverse Reactions to Wheat or Wheat
Components
Fred Brouns , Gonny van Rooy, Peter Shewry, Sachin Rustgi , and Daisy JonkersQ1
Abstract: Wheat is an important staple food globally, providing a significant contribution to daily energy, fiber, and
micronutrient intake. Observational evidence for health impacts of consuming more whole grains, among which wheat
is a major contributor, points to significant risk reduction for diabetes, cardiovascular disease, and colon cancer. However,
specific wheat components may also elicit adverse physical reactions in susceptible individuals such as celiac disease (CD)
and wheat allergy (WA). Recently, broad coverage in the popular and social media has suggested that wheat consumption
leads to a wide range of adverse health effects. This has motivated many consumers to avoid or reduce their consumption
of foods that contain wheat/gluten, despite the absence of diagnosed CD or WA, raising questions about underlying
mechanisms and possible nocebo effects. However, recent studies did show that some individuals may suffer from adverse
reactions in absence of CD and WA. This condition is called non-celiac gluten sensitivity (NCGS) or non-celiac wheat
sensitivity (NCWS). However, in addition to gluten, wheat and derived products contain many other components
which may trigger symptoms, including inhibitors of α-amylase and trypsin (ATIs), lectins, and rapidly fermentable
carbohydrates (FODMAPs). Furthermore, the way in which foods are being processed, such as the use of yeast or
sourdough fermentation, fermentation time and baking conditions used for breadmaking, may also affect the presence
and bioactivity of these components. The present review systematically describes the characteristics of wheat-related
intolerances, including their etiology, prevalence, the components responsible, diagnosis, and strategies to reduce adverse
reactions are being discussed.
Keywords: celiac disease, non-celiac wheat sensitivity, wheat, wheat allergy, wheat intolerances
Introduction
There are no data supporting the suggestion that either wheat-
Q2
based bread or pasta consumption is directly related to overweight
and diabetes, nor that gluten is a cause of addictive overconsump-
tion of food, contributing to overweight (Brouns, van Buul, &
Shewry, 2013; Jones, 2012). Nevertheless, it is increasingly sug-
gested that people should avoid eating gluten-containing grains,
in particular wheat, because this may cause overweight and a range
of related chronic diseases. Much of this information is based on
opinions and selective interpretation of limited data available, as
presented in social media and some popular books (Davis, 2012).
It is well known, however, that not all individuals are able to
tolerate all foods, meaning that they cannot ingest, digest, absorb
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and/or metabolize some specific foods or food components with-
out adverse physical or mental reactions. Very early observations of
wheat gluten intolerance stem from France in 1854 (Peyrat, 1854).
Nowadays, celiac disease (CD), in which individuals react ad-
versely to foods containing gluten proteins, is a well-characterized
disorder with an auto-immune component. The term gluten in-
tolerance has been used both as a synonym of CD as well as to
indicate that a patient experiences a clinical improvement after
starting a gluten-free diet (GFD), even when he/she does not
have CD. However, according to Ludvigsson et al. (2013), the
term gluten intolerance is nonspecific and carries inherent weak-
nesses and contradictions.
It is often suggested that the prevalence of wheat-related
disorders has increased over time, for which various plausible
explanations are being given. In addition to CD, some individuals
develop allergies to wheat proteins, which differ from CD in
the components that cause the reaction and the mechanisms.
More recently, a cluster of various intestinal and extra-intestinal
symptoms associated with the intake of wheat has been described
as Non-Celiac Wheat Sensitivity (NCWS, initially also named as
non-celiac gluten sensitivity, NCGS). Perceived adverse reactions
to wheat or wheat components can differ significantly with respect
to degree of disturbing quality of life, general discomfort, clear
diagnostic criteria, and criteria of belief without clear evidence.
To give more insight in these matters, the present article discusses
C© 2019 Institute of Food Technologists®
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aspects of these three types of wheat-related disorders in more
Q3
detail: 1) celiac disease, 2) wheat allergy (WA), and 3) NCWS.
For each of these, we will give a brief description followed by
discussions of etiology, prevalence, the components responsible,
diagnosis, and options for treatment. In an accompanying review
(Rustgi, Shewry, Brouns, Deleu, & Delcour, in review), we will
address wheat genetics and environmental factors as well as how
both impact on compositional differences, which in itself may
influence digestion and bioactive responses.
Celiac Disease
CD is defined as a chronic small intestinal immune-mediated
enteropathy precipitated by exposure to dietary gluten in genet-
ically predisposed individuals. Due to analytical complexity, the
total number of proteins present in the mature grain has never
been determined. However, proteomic analysis showed almost
500 proteins present in flour (Dupont, Vensel, Tanaka, Hurkman,
& Altenbach, 2011) and over 1,100 present in mature whole grain
endosperm (Skylas et al., 2000). Of these proteins, >100 are clas-
sified as gluten proteins, which may only differ in composition
by a few amino acids. They belong to the prolamins superfamily
of plant proteins, which include gliadins and glutenins in wheat,
secalin in rye and hordein in barley (Tatham & Shewry, 2008).
In the present paper, we focus primarily on wheat. In CD pa-
tients, long-term exposure to gluten results in variable degrees of
intestinal damage and in most patients, the intestinal mucosa will
recover on a GFD. According to the accepted definition, CD is a
chronic disease that may present itself in various ways, for which
the terms “classical CD,” “non-classical CD,” “refractory CD,”
“potential CD,” “latent CD,” and “transient CD” are being used.
For detailed definitions/description of the different terms used, the
reader can refer to Ludvigsson et al. (2013). Whether exposure of
an individual to gluten results in CD is determined by a combina-
tion of a specific genetic predisposition and environmental factors.
Approximately 25% to 40% of the population expresses the hap-
lotypes HLA-DQ2 or DQ8, which results in susceptibility to CD.
This percentage differs for different regions. It is estimated that
only 4% of individuals with the genetic predisposition DQ2 and
DQ8 actually develop CD. Seen this relatively small percentage,
there must other factors that, when having the genetic predisposi-
tion, trigger the initiation of the disease. In this respect, timing of
first gluten exposures at a young age (Pinto-Sanchez et al., 2016),
the dose of the (initial) gluten exposure (Koning, 2012), disease- or
drug/alcohol-related changes in intestinal permeability as well as
exposure to antibiotics and viral infections (Lebwohl, Sanders, &
Green, 2018) have been proposed. It should however be noted that
the exact impact of environmental factors in individual subjects is
not yet clear.
CD etiology
The high contents of proline and glutamine in the gluten pro-
teins result in partial resistance to digestion by gastrointestinal pep-
tidases. In case of an altered gut permeability, these undigested
gluten peptides can enter the lamina propria of the small intes-
tine via trans-cellular or para-cellular routes, leading to a cascade
of reactions causing adaptive immune responses and inflammation
as described in detail by (Fasano, 2012; Lebwohl et al., 2018).
When undigested gluten peptides enter the lamina propria of the
intestinal wall, via transcellular or paracellular routes, an adaptive
immune response is initiated after deamidation of the peptides by
the enzyme tissue transglutaminase (tTG). This deamidation to
glutamate boosts their affinity to the HLA-DQ2/8 receptor. An
inflammatory T cell response to HLA-DQ2/8-bound peptides
results from the recognition of a specific region (called epitope),
which is determined by its amino acid sequence, on the surface
of the antigen. The immune and inflammatory responses finally
lead to characterized increased numbers of intraepithelial lympho-
cytes and villous damage (see Figure 1). Many distinct gliadin- and
glutenin-derived T-cell epitopes exist, derived from either α-, γ -,
and ω-gliadins or from LMW/HMW glutenins. The activation of
gluten-reactive intestinal T cells, mediated by recognition of epi-
topes and enhanced by deamidation by tTG, enhancing receptor
affinity, is an decisive step in the development of CD. The char-
acterization of gluten T-cell epitopes, restricted by celiac disease
associated HLA-DQ molecules was essential in this respect. It has
been shown that not all gliadin epitopes are equally potent in T
cell stimulation. Alpha-gliadin (n 57–73), gamma-gliadin (n 139–
153), and omega-gliadin (n 102–118) appear to be the most active
peptides whereas γ -gliadin shows reduced activation. In addition,
it was shown that individual T cell, immune, and inflammatory
cascade responses to different gluten peptides may differ (Camarca
et al., 2009; Vader et al., 2003). Inflammatory mediators and sub-
stances that can pass through the intestinal wall can cause problems
elsewhere in the body such as gluten-induced dermatitis herpeti-
formis and neurological problems/ataxia (see further below).
The initial development of CD may be related to the food that
a child receives early in life. The effects of breastfeeding and the
timing of introduction of additional feeds, including bread (that is,
time of weaning) on the initiation of CD are not clear (Ludvigsson
& Fasano, 2012). It is recommended that the intake of small
quantities of gluten (usually bread) should start gradually before
the age of 6 months, often simultaneously with breastfeeding
(Ivarsson et al., 2013). The reason for this recommendation is
that the immune modulatory properties of breastfeeding and the
development of the intestinal microbiota would contribute to
the prevention of auto-immune diseases (Agostoni et al., 2008).
A number of studies have indicated a role of gut microbiota
perturbations and related gut-associated immune competence in
the etiology of CD (Chander, Yadav, Jain, Bhadada, & Dhawan,
2018; Nadal, Donat, Ribes-Koninckx, Calabuig, & Sanz, 2007;
Nistal et al., 2012, 2016; Olivares et al., 2018). Whether this
link is truly causal or a consequence of altered dietary patterns in
individuals that suffer from CD requires further study.
CD prevalence
It is estimated that approximately 1% of the global population
suffers from CD. However, a large variation in prevalence among
various countries has been reported (Catassi, Gatti, & Lionetti,
2015; Lionetti, Gatti, Pulvirenti, & Catassi, 2015). According to
the latest meta-analysis, the global seroprevalence of CD is 1.4%
with a range of 1.1% to 1.7%. However, based on analysis of
biopsy specimen, it is 0.7% with a range of 0.5% to 0.9% (Singh
et al., 2018). CD appears to be more common in women than in
men (ratio of 2 to 3:1). It is estimated that only one out of eight
people with CD has been diagnosed properly following clear
symptomatology, which suggests that many individuals remain
undiagnosed because of unrecognized (nonspecific) symptoms.
This is referred to as latent and silent CD. Rubio-Tapia, Lud-
vigsson, Brantner, Murray, and Everhart (2012) documented that
the prevalence of undiagnosed CD has dramatically increased
fourfold in the United States during the past 50 years. The authors
comment that the reasons for this increase are unknown and
speculate that the most likely explanation may be environmental,
such as a change in quantity, quality, or processing of cereals
2 Comprehensive Reviews in Food Science and Food Safety  Vol. 0, 2019 C© 2019 Institute of Food Technologists®
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Figure 1–A schematic illustration of progressive tissue changes in the small intestine. Type 0: Normal mucosa with Intraepithelial lymphocyte (IEL)
count<25 per 100 enterocytes; Type 1: Normal mucosa with an increased IEL count; Types 2 and 3 show flattening of the villi and increased IEL
counts and lymphocytes in the gut mucosa lining. IELs are presented as black dots. (adapted from (Cukrowska et al., 2017). Histological classifications
commonly used are Marsh, Marsh–Oberhuber and Corazza. For comparison see Ludvigsson et al. (2013).
(Rubio-Tapia et al., 2012). Overall 10% to 15% of CD patients
appear to suffer from dermatitis herpetiformis, defined as a
cutaneous manifestation of small intestinal immune-mediated
enteropathy precipitated by exposure to dietary gluten. It is
characterized by herpetiform clusters of pruritic urticated papules
and vesicles on the skin, especially on the elbows, buttocks, and
knees as well as IgA deposits in the dermal papillae. Gluten ataxia
(GA), defined as “idiopathic sporadic ataxia” is one of a number
of neurological manifestations attributed to CD (Ludvigsson et al.,
2013). Gluten ataxia has a prevalence of 15% among all ataxias
and 40% of all idiopathic sporadic ataxias (Hadjivassiliou, Sanders,
& Aeschlimann, 2015). The following factors have also been
suggested to play a possible role in CD etiology and modifying
our immunological sensitivity to gluten (Olivares et al., 2018):
major changes in the overall diet and increased hygiene, changes
in our gut microbiota composition and metabolism and related
gut-associated immune competence, an overall changed lifestyle
(less physical activity, more smoking), and changes in medicine
use (notably wider use of antibiotics and vaccines).
CD causing substances
Due to the high contents of proline and glutamine in some
parts of the gluten protein sequences, gluten is only partially
digestible by the enzymes present in the human intestine. Detailed
studies in several countries have led to the identification of the
indigested protein fragments that cause intolerance and sensitivity
reactions (DiGiacomo, Tennyson, Green, & Demmer, 2013;
Ludvigsson et al., 2013; Mamone, Picariello, Addeo, & Ferranti,
2011; Pastorello et al., 2007; Tatham & Shewry, 2008) and
allowed the amino acid sequences (epitopes) that stimulate T cells
(immunodominance) to be ranked (Anderson, Degano, Godkin,
Jewell, & Hill, 2000; Anderson et al., 2005; Shan et al., 2002,
2005; Tye-Din et al., 2010). As a result, a list of internationally
accepted gluten fragments, which play a role in CD, was reported
(Sollid, Qiao, Anderson, Gianfrani, & Koning, 2012). In addition,
there is a collection of >1,000 amino acid sequences of toxic and
immunogenic gluten peptides of the FARRP-Program of the
University of Nebraska (FARRP 2019). The number, type, and
distribution of epitopes, within a wheat type, may play a role in
the ability to elicit CD (Shewry & Tatham, 2016). Salentijn and
co-workers reported a significantly lower number of indigestible
peptides in several tetraploid species (Salentijn et al., 2009, 2013),
while a number of other studies have suggested that “modern”
hexaploid wheat types may induce more immune and inflamma-
tory reactivity than “ancient” tetraploid and diploid species and
hence result in more gastrointestinal problems in wheat-sensitive
individuals (Carnevali et al., 2014; Molberg et al., 2005; Pizzuti
et al., 2006; Sofi et al., 2010; Sofi et al., 2014; Spaenij-Dekking
et al., 2005; Vincentini et al., 2007, 2009). However, other studies
have shown that all types of wheat, including “ancient” species and
modern cultivars, induce some degree of immune reactivity and
thus should be avoided by CD patients (Colomba & Gregorini,
2012; Escarnot et al., 2018; Gregorini, Colomba, Ellis, & Ciclitira,
2009; Suligoj, Gregorini, Colomba, Ellis, & Ciclitira, 2013).
Van den Broeck et al. (2010) used antibodies to the Glia-α9 and
Glia-α20 epitopes and immunoblotting to classify modern bread
wheat varieties (1986 to 1998) and older types (1863 to 1982) as
having low, medium, or high reactivity. They showed that only
one of 36 modern wheat varieties had low levels of the 33-mer
peptide (containing one of the most harmful CD causing epitope
to which Glia-α9 antibody reacts), compared with 15 of 50 older
types and suggested that modern breeding may have contributed
to an increased content of highly CD reactive epitopes in modern
wheat varieties. However, Ribeiro et al. (2016) reported recently
a much more detailed study, comparing bread wheat (Triticum
aestivum var aestivum), spelt (T. aestivum var. spelta), and durum
wheat (Triticum turgidum var. durum), including modern cultivars
and old landraces from different countries and confirmed that
there is significant heterogeneity between wheat genotypes in
the levels of peptides containing T cell–stimulatory epitopes
(Ribeiro et al., 2016). This lead to the conclusion (in line with
Spaenij-Dekking et al., 2005) that targeted wheat breeding did
not result in increased levels of immunogenic epitopes, thus has
not contributed to increases in the incidence of celiac disease.
There is no evidence to support suggestions, particularly in
social media, that ancient tetraploid grains and spelt are more
tolerable for individuals suffering from CD. (Escarnot et al., 2018;
Gregorini et al., 2009; Ribeiro et al., 2016; Suligoj et al., 2013;
Vincentini et al., 2007, 2009). The recent comprehensive review
of “Peptides from gluten digestion: a comparison between old and
modern wheat varieties” by Prandi, Tedeschi, Folloni, Galaverna,
and Sforza (2017) concluded that the old varieties may actually
C© 2019 Institute of Food Technologists® Vol. 0, 2019  Comprehensive Reviews in Food Science and Food Safety 3
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contain more immunogenic sequences than modern varieties.
Kasarda (2013) and Shewry, Pellny, and Lovegrove (2016) provide
solid evidence that the gluten content in wheat has not increased
over time. In fact, total protein content of wheat, measured in
whole meal flour (determined as %N× 5.7), accounts for between
10% and 15% of the dry weight, with gluten proteins accounting
for 70% to 75% of the total grain protein (Shewry et al., 2016).
It is often suggested that the consumption of vital wheat
gluten (a co-product of the wheat starch industry) has increased
dramatically because of its incorporation as a functional additive
(as a binder and to improve texture) in bread and numerous other
food products. However, values for the actual levels of use of vital
gluten over the years are difficult to obtain. Based on various
assumptions, Kasarda (2013) calculated that the intake of vital
gluten has tripled since 1977, from 136 to 408 g per year or 0.37
to 1.12 g per day, per capita of the population. To what extent this
relatively small amount of vital wheat gluten is really influential in
CD etiology is a matter of debate, given that many times higher
intake of gluten consumed in bread (5 to 5.5 kg per year or 13.7
to 15.1 g per day; Kasarda, 2013).
One question that needs to be addressed is the precision of
analytical measurements. It should be recognized that the analysis
of gluten and gluten epitopes presents challenges due to the
difficulty in solubilizing gluten protein/peptides, variation in the
compositions of gluten hydrolysates and food matrices, the lack of
appropriate reference materials, the specificity of antibodies, and
the use of different methods for separation and quantification (Lex-
haller, Tompos, & Scherf, 2017; Schalk, Lang, Wieser, Koehler, &
Scherf, 2017; Schalk, Lexhaller, Koehler, & Scherf, 2017; Scherf,
2017; Scherf & Poms, 2016; http://www.wgpat.com/aims.html).
Schopf and Scherf (2018) reported that the relative proportions
of CD-immunogenic and -toxic peptides in gluten protein
fractions vary depending on genetic factors such as species and
cultivar in combination with environmental factors such as
climate, soil, fertilization, and agricultural practices (Ashraf, 2014;
Hajas et al., 2018). Variation in the precise amino acid sequences
of gluten proteins, due to substitutions, deletion, and insertions,
may affect the number of epitopes that are recognized by the
commonly used antibodies. Based on ELISA assays with several
antibodies, they concluded that care is required when using
ELISA analysis for gluten in foods to estimate their potential
activity and clinical relevance in CD (Schopf & Scherf, 2018).
In addition to gluten, it has recently been recognized that
non-gluten proteins may also elicit a significant antibody response
in patients with CD. Huebener et al. (2015) investigated the level
and molecular specificity of the antibody response to non-gluten
proteins of wheat in CD. Serum samples from patients and controls
were screened for IgG and IgA antibody reactivity to a non-gluten
protein extract from the wheat cultivar Triticum aestivum -Butte 86.
Compared with healthy controls, patients exhibited significantly
higher levels of antibody reactivity to non-gluten proteins. The
clinical relevance of these observations needs yet to be determined
. The main immunoreactive non-gluten antibody target proteins
were identified as serpins (a type of serine protease), purinins,
globulins, farinins, and α -amylase/protease inhibitors (ATIs).
ATIs are a group of enzyme inhibitors present in wheat, in at least
11 different isoforms (Junker et al., 2012). As gluten proteins,
ATIs are present primarily in the endosperm. They are also
present in isolated vital wheat gluten, which is often added to
foods.
The ATI content is affected by the environmental conditions
(for example, region, soil, fertilizer, humidity, shade, altitude, and
storage conditions). A comparative study of three different durum
wheat cultivars grown at three locations in Italy showed that the
effect of the growing conditions was greater than the differences
between cultivars (Prandi, Faccini, Tedeschi, Galaverna, & Sforza,
2013). Junker et al. (2012) and Zevallos et al. (2017) have built
a case for a role of ATIs in inducing inflammation and eliciting
an innate immune response, both of which are suggested to
potentiate the initiation of CD. These studies were carried out in
animal models and in vitro assays using isolated protein fractions
high in ATIs. These studies gave insights about possible mech-
anistic effects of isolated ATI fractions on human cell lines and
in mice. However, these fractions also contain other unidentified
components and have not been exposed to yeast/sourdough
fermentation and heat as takes place during food processing.
Accordingly, there is a clear need to initiate human trials with
oral exposure of 100% ATIs that also have been exposed to food
processing. Ultimately the challenge is to isolate ATIs from baked
bread. The developments outlined above show that the picture of
CD is very complex with many remaining questions.
Zevallos et al. (2017) extracted and characterized ATIs. Their
extracts resulted in preparations enriched with >60% bioactive
ATIs, in which 10 ATI isoforms were detected (isoforms 0.28,
0.53, 0.19, CM16, CM17, CM1, CM2, CM3, CMX1, and
CMX3). The authors studied in vitro the biological reponses to
exposure of these extracts, determined as release of chemokines
and cytokines (IL-8, CCL2/MCP-1, TNF-a, and IL-6) by human
THP-1 monocytes/macrophages. It was shown that the bioactiv-
ity responses to the most dominantly present isoforms 0.19, 0.28,
0.53, CM2, and CM16, in “ancient wheats” (einkorn and em-
mer) was significantly lower compared to bread wheat. They also
showed in C57BL/6 mice that were previously put on a GFD
that ATIs isolated from bread-wheat induced a 30% to 70% higher
in vitro TLR4 stimulatory bioactivity, as indicated by increased
numbers of activated macrophages (F4/80; MHCII) and dendritic
cells (CD11c, CD86, CXCR1-CD103). In addition, a significant
variation in ATI-related bioactivity was observed among hexaploid
wheats purchased from different regions, indicating that genetic,
geographic, and environmental growth conditions may play a role.
This ground breaking work also raised some important questions.
For example, the test grains were purchased from food stores or
collected at different geographic locations. In the commercial mar-
ket, grain samples are always mixtures of harvest quantities deliv-
ered by different farmers, who may not use the same seed material.
To put this more into context, in our current “Well on Wheat?”
project, we observed a 28% contamination with other seeds in
a 300 kg batch of market purchased spelt wheat (unpublished
results). In fact, to be able to conclude about the contents and bi-
ological activites of ATIs from any specific type of grain, certified
100% pure seed material should be obtained grown, harvested,
and packed under controlled conditions. Another question relates
to the purity of the extracted ATI fractions used in the in vitro
bioactivity essays. According to the authors, there was a significant
(approximately 30%) proportion of unknown compounds in the
isolated ATI fractions. Accordingly, it is possible that compounds
other than ATIs may play a role in the in vitro responses observed.
The above-raised concerns point to challenges for sourcing of pure
grains and performing careful descriptive analytics as a prerequisite
for human intervention trials. More recently, Geisslitz, Ludwig,
Scherf, and Koehler (2018) addressed both the issue of environ-
mental effects and of fractionation and quantitative measurement
of the predominant ATIs. In their work, the predominant ATIs
0.19 + 0.53, 0.28, CM2, CM3, and CM16 were quantitatively
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determined in the following wheats: bread-wheat, durum, spelt,
emmer, and einkorn. Of each of these wheats, 8 cultivars were
grown by the State Plant Breeding Institute, University of Hohen-
heim (Stuttgart, Germany) under the same environmental condi-
tions with the same agronomic treatments. A targeted LC–MS/MS
method using stable isotope labeled peptides as internal standards
was used. It was shown that einkorn contained very low to nonde-
tectable amounts of ATIs. However, spelt and emmer had higher
ATI contents than bread wheat. In the light of the work of Zevallos
et al. 2017, who observed lower bio-reactivity with einkorn and
emmer, compared to breadwheat, this raises important questions
about the total quantitiy as well the isoform distribution within
specific ATI extrtacts that are being used for clinical testing. In this
respect, precise analysis and quantification is required before being
able to conclude on biological cause-effects of specific grain types.
Lectins are another group of proteins in wheat that have been
suggested to be involved in adverse reactions. Based on their cell
binding properties, lectins have also been suggested to play a role
in CD by causing gut epithelial damage, allowing gluten epitopes
to pass the gut barrier (van Buul & Brouns, 2014). Lectins are
specific carbohydrate-binding proteins that are present in almost
all plants and their seeds, nuts, and fruits. They play a role in
important biological processes such as recognition of cells and
proteins, and thus protect the plant against external pathogens such
as fungi and other organisms. Some cultivated grains and legumes
have relatively high concentrations of specific lectins. Lectins are
present in the germ of the wheat grain and are called Wheat Germ
Agglutinins (WGA). There are no reported comparative studies of
the contents of lectins in different wheat varieties, or on possible
changes in lectin content or composition since the domestication
and intensive breeding of grains. Potential adverse effects of
products made of lectin-rich raw materials are based on animal
studies and are usually performed with high doses of raw extracted
(not heat-exposed) lectins. Because WGA is a heat-labile lectin, it
is assumed that it will lose its biological activity as a result of heat
exposure, for example, during baking and cooking. Studies using
pasta have shown that, although some uncooked whole grain pasta
do contain active WGA, cooking the food eliminates all the WGA
activity. At present there are no data on the effects of other (heat)
treatments such as baking, pasteurization, frying, and extrusion,
but it is probable that similar effects will be observed as those that
occur during the cooking of the pasta. Health effects of wheat
lectins were extensively reviewed by van Buul and Brouns (2014).
CD symptoms and diagnosis
The diagnosis of CD is usually based on, blood serology,
histological screening of small intestinal tissue obtained by biopsy
and eventually also determining the genetic predisposition for
CD. As biopsies are rather invasive, especially in children, avoiding
endoscopies in both adults and children, when possible, has
been proposed (Turner, 2018). In this respect, the European
Society for Pediatric Gastroenterology, Hepatology, and Nutrition
(ESPGHAN) advises refraining from taking a biopsy in cases where
the antibody titers exceed 10 times the normal level (Husby et al.,
2012). Below we present some general aspects of CD diagnosis:
 The diagnosis of CD should be considered in patients with:
1) Symptoms suggestive of CD, such as chronic diarrhea,
weight loss, malabsorption, abdominal pain, abdominal
distension, and growth retardation in children;
2) Iron deficiency anemia and/or osteoporosis;
3) In other diseases, in particular autoimmune diseases
associated with celiac disease.
 Diagnosis includes measuring levels of anti-tissue transglu-
taminase (anti-tTG IgA) and immunoglobulin A (IgA), as
well as total IgA and IgA EMA (endomysial antibody).
 In individuals who appear to be IgA-deficient, measuring a
combination of IgG-DGP (deamidated gliadin peptide), anti-
tTG IgA, and IgA EMA appears to be useful. IgG-DGP is
reported to be able to detect some IgA-sufficient patients who
are not identified by anti-tTG IgA tests.
 Key diagnostic findings further include the detection of char-
acteristic (albeit not specific) histopathologic changes in in-
testinal mucosal biopsies. Biopsy analysis should also include
intraepithelial lymphocytosis (>25 intraepithelial lympho-
cytes per 100 enterocytes), crypt hyperplasia, and various
grades of villous shortening (see Figure 1). Three histo-
logical classifications of CD are being used: Marsh, Marsh–
Oberhuber, and Corazza. A direct comparison of these clas-
sifications is given by Ludvigsson et al. (2013).
 Finally, conclusive diagnostic evidence that small-intestinal
enteropathy is caused by gluten is the histological improve-
ment in response to a GFD.
For a more detailed account of CD diagnosis, see Bai and
Ciacci (2017) and Lebwohl et al. (2018).
There are CD associated comorbidities that need to be
mentioned. As a consequence of the disappearance of the
surface-increasing villi/flattening of the gut mucosa (Figure 1),
the intestinal absorptive capacity declines, which will affect the
nutritional status. Related symptoms and consequences include
(fatty) diarrhea, weight loss, micronutrient deficiencies, and ane-
mia. However, some individuals may not present clear damage to
the intestinal mucosa. These people may have one or more general
complaints such as chronic fatigue, poor sleep, or headaches. In
children, growth retardation, muscle weakness, poor appetite,
and a tense abdomen have also frequently been observed. As in
adults, children with untreated CD often exhibit mood swings
and drowsiness (Lebwohl et al., 2018). The complaints of such
people are often not recognized as representing CD and as a result
such individuals are not tested or diagnosed, a situation that is
called subclinical CD, sometimes also referred to as potential CD.
CD threshold and solutions
The only effective therapy for CD is to go “gluten-free”;
however, it is not an easy lifestyle to adopt due to the social
constraints and ubiquity of gluten in food preparations. A large
number of commercial products, especially convenience foods
and ready meals, are either prepared using wheat flour or contain
one or more of wheat constituents such as wheat proteins,
starch, glucose syrup, or maltodextrins, as a filler processing aid,
binding agent, or stabilizing agent. It is important to clarify that
“gluten-free” not necessarily mean zero gluten, but that the label
can be applied to food products for individuals with CD, which
carry less than prescribed levels of gluten.
To determine the amount of gluten tolerated by celiac patients
in general, a number of gluten challenge studies with a variable
number of subjects, gluten doses, and diagnostic methods have
been undertaken. For example, working with a single patient
(Ciclitira, Evans, Fagg, Lennox, & Dowling, 1984) reached the
conclusion that 10 to 100 mg of gliadins induces no or slight
changes in the small intestine morphology of celiac patients,
whereas higher gliadin doses of 500 mg and 1 g cause moderate
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to extensive damage. In a later study, Hischenhuber et al. (2006)
reached a similar conclusion that 10 to 100 mg of daily gluten
intake is safe for consumption by celiac patients. In separate
studies, two Finnish groups also made similar observations and
concluded that 20 to 36 mg daily dose of gluten is safe for the
celiac patients on GFDs (Kaukinen et al., 1999; Peraaho et al.,
2003). On the other hand, Catassi et al. (1993) demonstrated
that 100 mg of gliadin intake by celiac patients per day for a
month caused deterioration of the small intestinal architecture
and a higher dose of 500 mg gliadin per day triggered even
more pronounced effects. Later, in a more elaborate double-blind
placebo-controlled study performed on 36 celiac patients, the
authors concluded that both 10 mg and 50 mg daily gluten
doses for 3 months are well tolerated, but that there is a trend
for mucosal changes to occur at the 50 mg dose. Reviewing
the existing data, Catassi and Fasano (2008) suggested that a
conservative threshold for gluten exposure for sensitive individuals
would lie between 20 and 100 ppm (=mg/kg). In a separate
study, Collin, Thorell, Kaukinen, and Maki (2004) took a very
different approach and analyzed gluten levels in a number of
different types of wheat starch (n = 24) and naturally gluten-free
flours (n = 59) consumed by 76 celiac patients who had been
on GFDs for 1 to 10 years. The range of gluten found in these
products was 0 to 200 ppm and the total daily flour consumption
for these individuals was 10 to 300 g. Based on these estimates,
they calculated the daily gluten exposure levels and used this data
to suggest a threshold of 100 ppm gluten (Collin et al., 2004).
However, despite these studies, a consensus on the critical limit
or threshold for gluten intake has still not been reached. This
is to be attributed to wide variability among celiac patients, as
demonstrated by an extensive double-blind placebo-controlled
multicenter investigation for the gluten toxicity (10 to 50 mg/day)
on 40 celiac patients. In this study, the patients were administered
daily a capsule containing 0, 10, or 50 mg of gluten for 90 days
and analyzed for clinical, serological, and histological changes in
their small intestines. The study reported a high variability among
patients in terms of gluten sensitivity. Some patients showed
intestinal symptoms after ingesting only 10 mg of gluten a day
while other patients showed no histological symptoms even after 3
months daily challenge with 50 mg of gluten (Catassi et al., 2007).
Because of the variability in the results and the wheat con-
sumption levels, different countries allow different gluten levels
in the products for consumption by the celiac patients. For
example, North European countries such as Denmark, Norway,
and Sweden permit up to 200 ppm gluten in the food for the
celiac patients. By contrast, the South European countries such
as Spain, Italy, Greece, and Croatia adopted a more conservative
limit of 20 ppm gluten in the “gluten-free” products. Based on
clinical data, an intermediate limit of 100 ppm was adopted by
Finland. On the other hand, the Australia and New Zealand Food
Agency (ANZFA) recognizes two classes of foods, “gluten-free
foods” with no detectable gluten and “low-gluten foods” with
no more than 200 ppm gluten. However, the Canadian definition
for “gluten-free” is more general, with “gluten-free” meaning a
food without wheat, including spelt and Khorasan wheat, or oats,
barley, rye, triticale, or any part thereof. On August 5, 2013, the
U.S. Food and Drug Administration also set a limit of 20 ppm
gluten in allegedly “gluten-free” products.
A decision on the threshold depends not only on the maximum
tolerable dose of gluten in food but also on the amount of
“gluten-free” product(s) consumed daily, which depends on the
eating preferences in a region and per subject. The results of
the food challenge study indicated that 200 ppm is not a safe
threshold as the gluten intake limit of 50 mg could be reached
with the consumption of 250 g of allegedly gluten-free product(s).
A 100 ppm limit that allows 100 mg gluten in a kg of food is also
impractical, as in European countries consumption of gluten-free
products could be as high as 500 g per day (Gibert et al., 2006).
However, the threshold of 20 ppm keeps the intake of gluten from
‘gluten-free’ food well below the 50 mg amount, thus allowing
a safety margin for the variable gluten sensitivities and dietary
habits of the different patients. This led the Codex Alimentarius
Commission in its current draft proposal to set the following
definition for the gluten-free commodities: “a) consisting of or
made only from ingredients which do not contain any prolamins
from wheat, durum wheat, rye, barley, oats or any Triticum species
such as spelt (Triticum spelta L.,), kamut (Triticum polonicum L.) or
their crossed varieties with a gluten level not exceeding 20 mg/kg
in total based on the foods ready for consumption; or b) consisting
of ingredients from wheat, rye, barley, oats or any Triticum species
such as spelt (Triticum spelta L.,), kamut (Triticum polonicum L.) or
their crossed varieties, which have been rendered “gluten-free”,
with a gluten level not exceeding 100 mg/kg in total based on
the foods ready for consumption; or c) any mixture of the two
ingredients as in a) and b) with a gluten level not exceeding (100
mg/kg) in total based on the food ready for consumption.”
The immunogenicity of oats is controversial, as it can be toler-
ated by most but not all individuals with celiac disease, however, to
keep the regulations similar throughout the world its use is gluten-
free foods for the dietary management of celiac disease is regulated
much like wheat by the Codex Alimentarius Commission. It is not
clear if the oat tolerance observed in individuals with celiac disease
is due to the differences in chemical structure between gliadin and
avenin or to the lower avenin content of oat flour in comparison
with the high gliadin content of wheat flour. Based on a number
of studies, at present, the scientific consensus is 50 g of oats per day
are well tolerated by most individuals with celiac disease (Catassi &
Fasano, 2008; Gilissen, van der Meer, & Smulders, 2016). In this
respect, it should be mentioned that oat is often contaminated with
small quantities of either wheat or barley. The contamination may
stem from what was still present in the field (due to kernels lost in
the past and sprouted and grow again), or during transport and food
processing in environments where also wheat and barley was/is
present. Such contamination may be sufficient to induce problems
in individuals who are sensitive to very small amounts of gluten.
Recent studies indicate that food processing and events in
the gastrointestinal tract may have effects on the gluten proteins.
Gianfrani et al. (2015) provided evidence that extensive in vitro
gastrointestinal hydrolysis drastically reduced the immune stimu-
latory properties of Triticum monococcum gliadin. Mass spectroscopy
(MS)-based analysis showed that several Triticum monococcum
peptides, containing known T-cell epitopes, were degraded
during the gastrointestinal treatment, whereas many of Triticum
aestivum gliadin survived gastrointestinal digestion. More recently,
Perez-Gregorio, Dias, Mateus, and de Freitas (2018) monitored
the gastrointestinal effects on specific CD epitopes by means of an
in vitro gastrointestinal digestion model that included incubation
with brush-border membrane enzymes. Gluten hydrolysates
were characterized by MS and the immunogenic peptides were
identified by searching for the main T-cell stimulating epitopes.
The immunogenic potential of gluten hydrolysates was further
analyzed by enzyme-linked immunosorbent assay (ELISA).
The results showed that the composition of the gluten hy-
drolysates depended on the digestion time and protein structural
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Table 1–Different features of Celiac Disease (CD), Wheat Allergy (WA), and Non Celiac Wheat Sensitivity (NCWS) (modified from Catassi et al. (2015).
CD WA NCGS
Time interval between
gluten exposure and onset
of symptoms
Weeks - years Minutes - hours Hours - days
Pathogenesis Autoimmunity (innate and adaptive
immunity)
Allergic immune response Immunity? (innate immunity?)
HLA HLA-DQ2/8 restricted (97%
positive cases)
Not HLA-DQ2/8 restricted (35-40%
positive cases as in the general
population)
Not HLA-DQ2/8 restricted (50%
DQ2/8-positive cases)
Autoantibodies Almost always present Always absent Always absent
Enteropathy Almost always present Always absent (eosinophils in the
lamina propria)
Always absent (slight increase in IEL)
Symptoms Both intestinal and extra-intestinal (not distinguishable between these three gluten-related disorders) Common intestinal
symptoms: bloating, abdominal pain, diarrhea, nausea, epigastric pain, alternating bowel habits.
Common extra-intestinal symptoms: lack of wellbeing, tiredness, headache, anxiety, foggy mind.
Complications Co-morbidities, long-term
complications
Absence of co-morbidities, short-term
complications (including
anaphylaxis)
Absence of co-morbidities and
long-term complications (long
follow-up studies needed to
confirm it)
GI, gastrointestinal; GS, gluten sensitivity; IEL, intraepithelial lymphocytes.
characteristics. Glutenin oligopeptides were degraded faster
whereas oligopeptides from gliadin, mainly from α-gliadin
oligopeptides, remained intact for a long time. Peptides contain-
ing the α-9 gliadin epitope (PFPQPQLPY) remained intact even
after 180 min digestion in intestinal brush-border membrane
vesicles. The in vitro studies discussed above need to be confirmed
in vivo. An important conclusion is that not all peptides were de-
graded, suggesting that they are potentially unsafe for CD patients.
Shewry and Tatham (2016) discussed the possibility of im-
proving wheat by selective breeding and application of modern
molecular approaches (transgenesis and gene editing) to remove
celiac epitopes but retaining functionality for food processing,
however, they concluded that this is a formidable challenge
due to the complex multigenic control of the gluten protein
fraction. Recently, Sanchez-Leon et al.2018) and Jouanin, Boyd,
Visser, and Smulders (2018) have used a CRISPR/Cas9-based
approach to induce mutations/small deletions, respectively, in
α-gliadin and g-gliadin genes, yielding wheat lines with reduction
immunogenicity and acceptable dough quality in laboratory-scale
breadmaking trials. However, these genome-edited wheat lines
still contain celiac-toxic gluten proteins and therefore cannot
be regarded as safe for CD patients. For more detail see the
accompanying review by Rustgi et al. (in review).
Wheat Allergy
An allergen is defined as a substance that causes an immediate
immune reaction upon exposure by ingestion, inhalation or skin
contact. Wheat belongs to the eight foods (milk, eggs, fish, crus-
tacean shellfish, tree nuts, peanuts, wheat, and soybean) identified
by Codex Alimentarius (Codex Alimentarius Commission, 1992)
Q4 as being responsible for approximately 90% of all food allergies in
children (Battais, Richard, Jacquenet, Denery-Papini, &Moneret-
Vautrin, 2008). Of these food groups wheat is responsible for caus-
ing 11% to 25% of the total food allergy prevalence (Hirschenhu-
ber et al., 2006). Below we will describe briefly the most common
forms of wheat related allergies. For an overview of characteristics
and symptoms associated with CD, WA, and NCWS, see Table 1.
WA etiology
Allergic reactions to wheat, in contrast to CD, involve IgE
(immunoglobulin) antibodies. Depending on the route of allergen
exposure and the underlying immunological mechanisms, WA is
classified into (1) immediate food allergy; (2) wheat-dependent
exercise-induced anaphylaxis (WDEIA), (3) respiratory allergy,
and (4) contact urticaria. IgE antibodies play a central role in
the pathogenesis of these disorders. In WA, the body reacts to
the protein via antigen-presenting cells that activate B-cells to
produce allergen-specific immunoglobulin IgE antibodies, which
bind to mast cells that are present throughout the body. If two or
more IgE antibodies on the surface of a mast cell are linked by
an allergen, the mast cell is activated and histamine is secreted.
This leads to symptoms such as swollen membranes of the mouth
and throat, difficulty in swallowing, shortness of breath, diarrhea,
vomiting, abdominal pain, asthmatic reactions, and rashes. In
addition, a whole-body reaction leading to a sudden severe drop
in blood pressure can lead to anaphylactic shock or even death
(Hadjivassiliou et al., 2015). For detailed reviews related to cereal
induced allergies see Cianferoni (2016); Gilissen, van der Meer,
and Smulders (2014); Inomata (2009); Pasha et al. (2016); Sapone
et al. (2012); Scherf (2017); and Tatham and Shewry (2008).
WA prevalence
Food allergy in general occurs in more than 6% of children and
in almost 3% of adults. Usually the allergy is to specific proteins
in the food consumed. Figures for WA among children vary from
<0.1% to 1%, depending on age and country (Hischenhuber
et al., 2006; Kotaniemi-Syrjanen et al., 2010; Sapone et al.,
2012). However, a large meta-analysis has shown that the general
prevalence is at most approximately 0.2% (Zuidmeer et al., 2008).
Generally speaking, about half of children “outgrow a food
allergy over time.” Depending on the type of allergy, this
percentage can be lower (peanut) or higher (milk). With regard to
WA, studies show that more than 80% of children have outgrown
their WA by their eighth year, and 96% before their 16th year
(Kotaniemi-Syrjanen et al., 2010). It explains why the number
of adults with WA (0.25%, Zuidmeer 2008) is much lower than Q5
the number of people with CD. In adults the prevalence of food
allergies appears to be higher in women than in men (Afify
& Pali-Scholl, 2017). The prevalence of specific subcategories
of wheat allergy such as WDEIA, bakers’ asthma, and contact
urticaria is a fraction of the total prevalence of 0.25%, thus,
is small. As example, WDEIA was calculated to be 0.017% in
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Japanese children (Aihara et al., 2001). In adults the prevalence
of WDEIA is unknown (Baccioglu, Kalpaklioglu, & Altan,
2017). In recurrent urticaria patients, wheat allergy, diagnosed
as wheat-induced urticaria, was observed in 6.8% of this patient
group. The prevalence of wheat induced chronic urticaria in
adults was estimated at 0.5% to 5% (Bernstein et al., 2014). The
incidence of wheat induced asthma is high among bakers with a
figure ranging from 1% to 10% and bakers associated rhinitis with
an incidence of 18% to 29% (Cianferoni 2016).
WA causing substances
Two proteins types generally recognized to induce allergy in
most cases are ATIs and monomeric gliadins (α/β-, γ -, and
ω-gliadins) commonly known to be involved in CD etiology but
now also recognized for being involved in IgE-modulated allergic
reactions (Pastorello et al., 2007; Tatham & Shewry, 2008). To a
lesser extent, reactions to LMW-glutenins, lectins (WGA), and
possibly also lipid transfer proteins (LTPs) may occur (Baccioglu
et al., 2017; Brans, Sauer, Czaja, Pfutzner, & Merk, 2012; Cian-
feroni, 2016; Gilissen et al., 2014; Mamone et al., 2011; Scherf,
Koehler, & Wieser, 2016). Cross-reactions may occur with related
proteins present in other grains. For example, Rye γ -70 and γ -35
secalins and barley γ -3 hordein cross-react with wheat ω-5 gliadin
(Palosuo, Alenius, Varjonen, Kalkkinen, & Reunala, 2001).
It has long been known that ATIs play a role in bakers’ asthma
(flour dust allergy) and food allergy to wheat (Pastorello et al.,
2007; Tatham & Shewry, 2008). Recently, Zevallos et al. (2018)
and Bellinghausen et al. (2018) showed that ATI’s exacerbate aller-
gic reactions in mice. ATIs are heat resistant and it has been shown
that ATIs present in cooked wheat (5 min at 100°C) can still cause
an allergic reaction (Pastorello et al., 2007). Interestingly, some
people have been reported to show stronger allergic reactions
to cooked compared to raw wheat (Tatham & Shewry, 2008).
However, Ge´linas and Gagnon (2018) provided evidence that
ATIs present in thoroughly heated, cereal foods lose their enzymic
inhibitory activity. In this respect it should be noted that although
inhibitory activity may be lost due to heat denaturation, the intact
protein is still present in the food. In other words, a change of
α-amylase activity does not necessarily mean that there is also
a loss of inflammatory and/or immune reactivity in susceptible
individuals. Nonspecific lipid transfer proteins (LTPs) may also
play a role in WA, but this is less well known (Gilissen et al.,
2014; Pastorello et al., 2007; Tatham & Shewry, 2008). LPTs are
low molecular weight proteins present in many plants, including
cereal seeds and are well characterized as heat-resistant allergens.
WA symptoms and diagnosis
For the diagnosis of wheat allergy, patients must have repro-
ducible symptoms, which occur quickly (that is, minutes to
hours) after wheat exposure. For an overview of characteristics
and symptoms associated with CD, WA, and NCWS, see Table 1.
Wheat allergy can be diagnosed by a combination of a blood test
and a skin test. A blood test will determine whether specific IgE
antibodies to allergens (in this case wheat proteins) are present,
while a skin test checks for the reaction, after subcutaneous
injection, to a very small quantity of wheat proteins.
However, the presence of IgE antibodies against wheat in blood
does not always mean that there is an active (food) allergy. Sim-
ilarly, the skin test does not always result in a conclusive diagnosis
(Sapone et al., 2012). Final proof can be obtained by a wheat chal-
lenge test, executed in a double blind, placebo-controlled setup.
WA threshold and solutions
People suffering from WA need to completely avoid products
containing wheat depending on the severity, and must be aware
of possible cross-contamination of foods with traces of wheat.
Although rare, in some cases allergic cross-reactivity with other
grains (barley, rye), and even with fruits can occur. Children with
wheat allergies usually react to smaller amounts of wheat than
adults (Gilissen et al., 2014). In the literature, it is reported that
80% of children react to less than 2 g of wheat protein, while for
a small subgroup less than 10 mg may even be a problem. On the
other hand, the nature of the symptoms in children is often less
severe (mainly rashes, respiratory and intestinal cramps) than in
adults (more frequent anaphylactic shock, facial edema, and severe
intestinal symptoms and esophageal irritation; Hischenhuber
et al., 2006). However, it is recommended that self-reported
symptoms should be treated with caution. Suspected allergy
reactions to plant food should be confirmed with double-blind,
placebo-controlled challenge tests (Zuidmeer et al., 2008).
Excellent reviews of WA, which cover the background, diagnosis,
and management can be found in Battais et al. (2008), Gilissen
et al. (2014), and Cianferoni (2016).
Non-Celiac Gluten/Wheat Sensitivity
During recent years a third group of people has been classified
who experience symptoms after eating wheat products, but have
been diagnosed not to suffer from either WA or CD. Mostly these
individuals are self diagnosed wheat intolerant/sensitive. In these
individuals, irritable bowel syndrome (IBS)-like gastrointestinal
symptoms and extra-intestinal complaints occur, which improve
on a gluten-free diet. This group of patients is referred to as
“non-celiac gluten sensitivity” (NCGS), or the more recently,
“non-celiac wheat sensitivity” (NCWS). Di Sabatino emphasizes
that NCWS is not a homogeneous disease syndrome (such as
CD and WA), but rather a heterogeneous syndrome (Di Sabatino
& Corazza, 2012). It is probable that the underlying causes and
mechanisms are not the same for all people with NCWS and that
reactions may be caused by different components of wheat or grain
(products) and involving different host factors. Ludvigsson et al.
(2013) defined NCGS as follows: one or more of a variety of im-
munological, morphological, or symptomatic manifestations that
are precipitated by the ingestion of gluten in individuals in whom
CD has been excluded. However, despite the word “gluten” in
the currently most cited definition “NCGS,” it is far from certain
that the gluten is the (main) cause of the symptoms observed. The
new term “NCWS” was adopted since it was noted that gluten
(NCGS) may not be the real cause (Biesiekierski, Peters, et al.,
2013; Skodje et al., 2018). For that reason, we will use the term
NCWS as most appropriate in the remainder of this article.
NCWS etiology
The etiology of NCWS is not completely clear. Intestinal
symptoms of NCWS do overlap with CD, but enteropathy (mu-
cosal damage and flattening the brush border) is absent. Serology is
generally negative, though increases in anti-tissue transglutaminase
(tTG) antibodies, EMA, and DGP antibodies have been reported
(Catassi, Elli, et al., 2015). By contrast to CD, NCWS may show
signs of an activated innate immune response, whereas, in line with
CD, an increased mucosal permeability, may also occur. Cash et al.
(2011) found antibodies that could be related to CD (specifically
against gliadin) in 7.3% of the IBS patients (total: n = 492) that
they examined. However, in only 0.4% was the diagnosis of CD
confirmed. Carroccio et al. (2012) observed in a double-blind
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study that 276 (30%) from 920 diagnosed IBS patients undergoing
an elimination diet and a subsequent double blind placebo con-
trolled challenge of these, were suffering from wheat sensitivity as
they became asymptomatic (VAS score <10) on the elimination
diet and showed symptoms again after the challenge. Two hundred
six of the patients (>22.4%) were diagnosed with multiple food
hypersensitivity, as they also reacted to the DBPC challenge with
cow’s milk protein, egg (n = 120), and/or tomato (n = 112). Only
70 individuals (7.6%) reacted exclusively to wheat (Carroccio
et al., 2012). The group that reacted only to wheat demonstrated
more association with CD-related biomarkers. For example, 75%
of them had the HLA-DQ2/-DQ8 haplotype and 94% of these
were found to have increased numbers of lymphocytes in the
duodenum. In addition, in one-third of this group of patients
intestinal biopsy was positive for EMA, which may indicate a
prestage of CD. An overview of different features of CD, WA,
and NCWS is given in Table 1 below. For a detailed overview
of characteristics and symptoms associated with CD, WA, and
NCWS, see Catassi et al. (2017) and Catassi, Elli, et al. (2015).
NCWS prevalence
An international market research agency reported in 2013
that 35% of adult Americans indicated that they are reducing
their gluten intake or following a gluten-free diet because they
perceive gluten-free foods to be healthier (Watson, 2013). Such
high numbers are, however, in contrast with data from other large
population studies and may vary between countries. In the U.S.
National Health and Nutrition Examination Survey 2009–2010
(n = 7,762, CD patients excluded) only 0.55% answered “yes”
to the question “are you on a gluten-free diet?” DiGiacomo et al.
(2013) and Rubio-Tapia et al. (2012) reported similar values:
according to their research some 0.63% of North Americans
follow a gluten-free diet. Between 2004 and 2010, 5,896 patients
visited the Centre for CD of the University of Maryland (USA)
with CD/WA-like symptoms. Of these patients, 6% met the
criteria for NCWS (Sapone et al., 2012). Based on these data, the
prevalence in the general population was therefore estimated to
be lower than 6%. Two European studies observed a prevalence
of respectively 13% self-reported NCWS in a general population
cohort of 1,002 men and women and 6.2% self-reported NCWS
in a general population cohort of 785 adults (Aziz et al., 2014;
van Gils et al., 2016). Seventy-nine percent of these individuals
appeared to be females having a significantly increased prevalence
of anxiety, depression, chronic fatigue syndrome, and food
allergies/intolerances. These observations indicate significant
psychiatric comorbidities. In one study, it was noted that
hypnotherapy was as effective as a diet low in Fermentable Oligo,
Di-, Monosaccharides, and Polyols (FODMAP) in reducing such
symptoms (Peters et al., 2016). It should also be noted that all
food allergies, including wheat allergy, are more prevalent in
women than in men (Afify & Pali-Scholl, 2017). The positive
predictive value (PPV) of gluten-related symptoms (defined
as the probability that someone with the symptom related to
gluten really has NCWS) is very low. For example, Capannolo
et al. (2015) studied 392 patients complaining of gluten-related
symptoms. It was found that 26 of these (6.63%) were affected by
CD, two (0.51%) by WA, and 27 were diagnosed with NCWS
(6.88%). The remaining 337 patients (85.96%) did not experience
any change of symptoms with a gluten-free diet. The authors
conclude that self-perceived gluten-related symptoms are rarely
indicative of the presence of NCWS. Due to the current broad
consensus definition, it is not yet possible to make a reliable
estimate of the number of people suffering from NCWS. It is
expected that this will be higher than the number of people
with CD, but reliable (more or less substantiated) estimates are
scarce and range from 0.5% to 10% of the population (Ludvigsson
et al., 2013). The discussion above highlights the complexity of
wheat-related responses and the need for well-designed studies.
NCWS causing substances
Substances that are often suggested to be involved in NCWS are
gluten, non-gluten proteins, and FODMAPs. Several intervention
studies have been carried out that investigated the reactions of
people with (alleged) NCWSwhen put on a diet with and without
gluten and/or wheat, in comparison with a control group. Most of
the studies were done in groups of patients with IBS, who reported
benefits from avoiding wheat. In the studies that showed significant
differences, these mainly involved complaints reported after expo-
sure to wheat/gluten in blind challenges studies (the participant
in the test did not know whether wheat/gluten or placebo was
present in the food). In most studies, no changes were observed in
intestinal permeability or in specific (immunological) biomarkers
that could explain a potential underlying cause of NCWS. In
a few of the studies, CD could not be ruled out because there
was no information about the tissue status of the small intestine
(Bucci et al., 2013; Jones, McLaughlan, Shorthouse, Workman, &
Hunter, 1982; Sapone et al., 2012) whereas in some other studies,
patients showed mild intestinal damage which was consistent with
the Marsh 1 stage of CD (Figure 1). These people may therefore
have been erroneously labeled as NCWS patients and would
probably be diagnosed with CD after further investigation. On the
other hand, such slight damage of the intestinal wall and its asso-
ciated permeability can also occur after extreme physical exercise,
drug and/or excessive alcohol use, as well as are reported in people
with IBS. According to various studies, there is also a so-called
“nocebo” effect (a negative expectation effect). For example, a
double-blind placebo-controlled crossover study by Biesiekierski
et al. (2013) showed a significant worsening of overall gastroin-
testinal symptoms irrespective of the intervention (that is, placebo,
low-gluten, or high-gluten diet) and interestingly, the symptom
scores were highest with the first dietary challenge received. So
an order effect was observed, indicating a strong anticipatory
symptomatic (that is, nocebo) response, independently of the
nature of the dietary challenge (Biesiekierski, Peters, et al., 2013).
It should be noted that a clear relationship of NWCSwith gluten
alone has not been confirmed by several studies, as they investi-
gated wheat (products) and not gluten per se (Biesiekierski, Muir,
& Gibson, 2013; Vazquez-Roque et al., 2013). In these studies,
people were also exposed to other components such as LTPs, ATIs,
and fermentable carbohydrates (that is, FODMAPs), normally
present in wheat. To date, there have been no studies carried out
in which wheat-sensitive people were tested for their reaction to
these individual wheat components or combinations of them. In-
terestingly, studies using tetraploid durumwheat types of older ori-
gin were found to reveal less symptoms in IBS patients when com-
pared to modern wheat (Sofi et al., 2014). It may be that differ-
ences in genetics, compared to hexaploid breadwheat, and related
differences in the composition of these grains play a rol. (Carnevali
et al., 2014; Ge´linas & McKinnon, 2016; Sofi et al., 2010, 2014).
FODMAPs are defined as Fermentable Oligo, Di-, Monosac-
charides, and Polyols. An increasing number of studies have shown
that a low FODMAP diet is associated with symptom improve-
ment in (subgroups of) patients with IBS (Barrett, 2017; Maagaard
et al., 2016; Schumann et al., 2018). A number of studies that
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looked specifically at the effect of a low FODMAP diet in IBS
patients reported significant relief of symptoms, mainly abdominal
pain and bloating, likely due to less colonic fermentation and asso-
ciated gas formation (Barrett & Gibson, 2012; Staudacher, Whe-
lan, Irving, & Lomer, 2011; van der Waaij & Stevens, 2014). Stud-
ies on long-term effects are however hardly available. Though, also
given the large symptom overlap between IBS and NCWS, wheat-
based products are increasingly being listed as foods that con-
tain fermentable carbohydrates (mainly fructose-containing poly-
mers called fructo-oligosaccharides or fructans), being classified as
FODMAPs, and may lead to symptoms. However, the quantities
of fructans in wheat-based foods are low and far below the levels
that may cause abdominal distress in healthy individuals. For ex-
ample, the total fructans content in two slices of bread amounts to
<0.5 g. In a 35 to 50 g cup of breakfast cereals, this is about 1 g and
in pasta about 0.5 g per 150 g portion. Furthermore, it should be
noted that FODMAPs will be significantly degraded by the yeast
and/or active starter culture during dough fermentation which
may lead to complete degradation in sourdough systems (Brouns,
Delzenne, & Gibson, 2017). However, there is sound evidence
that (long-term) avoidance of fermentable dietary fibers can impair
favorable gut microbiota composition and metabolism, gut func-
tion, and health and that eliminating grains from the diet to avoid
FODMAPs also results in the elimination of a wide range of other
components that are known to be beneficial (Brouns et al., 2017).
NCWS symptoms and diagnosis
Intestinal symptoms commonly reported are as follows: abdom-
inal pain, epi-gastric pain nausea, gastric acid reflux, episodes of
constipation, and diarrhea. Most frequent extra-intestinal symp-
toms are poor sleep, tiredness, lack of well-being, headache, foggy
mind, joint/muscle pain, and skin rash/dermatitis. Based on these
observations, it is clear that there is significant overlap in symp-
tomatology between NCWS and CD (see also Table 1). At present
there is no diagnostic test available for NCWS. Diagnosis is com-
plicated by the fact that people report self-diagnosed symptoms
that overlap with CD and WA. Moreover, there is also a signifi-
cant overlap between symptoms perceived by individuals suffering
from IBS. About 70% of IBS patients consider their symptoms
to be food related, with wheat ranking in the top five (Rajilic-
Stojanovic et al., 2015). In 1982, Jones and colleagues reported that
of the 21 IBS patients tested, nine reported symptoms after eating
wheat without the presence of CD (according to the then applica-
ble diagnostic criteria; Jones et al., 1982). IBS is known to be asso-
ciated with psychological factors, altered microbiota composition,
motility, and/or visceral perception and high placebo response
rates (Borghini, Donato, Alvaro, & Picarelli, 2017; Dolan, Chey, &
Eswaran, 2018; Ford &Moayyedi, 2010; see Table 1 and Figure 2).
Caio, Volta, Tovoli, and De Giorgio (2014) showed that the 93%
of the 44 included subjects that suffered from NCWS test positive
for anti-gliadin IgG antibodies and improved significantly follow-
ing wheat/gluten-free diets. More recently, Uhde et al. (2016)
reported comparable results and showed that reported sensitivity
to wheat in the absence of CD was associated with significantly
increased levels of soluble CD14 and lipopolysaccharide-binding
protein, as well as antibody reactivity to microbial antigens, indi-
cating systemic immune activation. It should be noted that affected
individuals have significantly elevated levels of fatty acid-binding
protein 2, a marker of intestinal damage, and correlates with the
markers of systemic immune activation. Furthermore, about 50%
of NCWS individuals are positive for first-generation anti-gliadin
antibodies, mainly IgG, but NCWS is unrelated to the CD genetic
Figure 2–Significant overlap of substances causing symptoms in gluten
related disorders and in irritable boweel syndrom (IBS).
markers HLA-DQ2 and -DQ8 (Volta, Caio, Tovoli, &DeGiorgio,
2013). The above findings indicate that NCWS is associated with
several nonspecific symptoms and factors, complicating an accurate
diagnosis. At present, suggestions for a possible diagnostic aproach
for NCWS have been given by Volta et al. (2013), as follows:
 Gluten ingestion typically elicits the rapid occurrence (in a
few hours or days) of intestinal and extra-intestinal symptoms;
 Symptoms disappear quickly (in a few hours or days) after the
elimination of gluten from the diet;
 Reintroduction of gluten causes the rapid recurrence of symp-
toms;
 Celiac disease must be ruled out by means of negative serology
(endomysial and tissue transglutaminase IgA antibodies) and
a duodenal biopsy on a gluten-containing diet;
 Wheat allergy tests (specific IgE as well as skin prick tests),
performed on a gluten-containing diet, must be negative;
 A double-blind, placebo-controlled gluten challenge test is
needed in each suspected patient to confirm the diagnosis
and to exclude a placebo effect induced by gluten exclusion.
One important remark needs to be made here. When stating
that symptoms disappear quickly (in a few hours or days) after
the elimination of gluten from the diet, one should be aware that
gluten avoidance includes avoidance of all other components of
wheat (including non-gluten proteins and FODMAPs).
NCWS threshold and solutions
For many cases of “NCWS” in IBS patients, a GFD and/or
wheat-free diet is advised (Nijeboer, Mulder, & Bouma, 2013).
However, there is no reliable information on the threshold
of wheat consumption at which people develop complaints.
Furthermore, recent studies suggested that FODMAPs and/or
probably ATIs, rather than gluten, may be the cause of intestinal
distress. The threshold value will depend strongly on the causative
component, and the sensitivity of the patient to that component.
With regard to dietary fiber, which includes some FODMAPs
such as fructans, it is essential to understand that for a healthy
intestinal microbiome and intestinal function, the consumption of
fermentable carbohydrates is generally recommended. The pro-
duction of short chain fatty acids and gas during the fermentation
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of indigestible carbohydrates is not an aspect of disease but merely a
normal physiological process in the large intestine, with a range of
beneficial effects. Whether the consumption of just 0.5 g to a little
more than 1 g of FODMAPs, as present in most breads, can indeed
lead to disruptive gas formation is still unclear. As mentioned
above, spelt wheat has been reported to have a somewhat lower
FODMAP content (1.257 ± 0.213ab g/100 g DM) compared to
bread-wheat (mean value 1.568 ± 0.204 g/110 g DM) (Ziegler &
Steiner, 2016). However, it is doubtful that the small differences
in the FODMAP contents of different types or cultivars of wheat
have any clinical relevance. To what extent this may play a role for
some of people with IBS who say they benefit from eating spelt
products instead of modern bread wheat products deserves further
investigation. Ziegler and Steiner (2016) commented that for
wheat bakery products suitable for consumption by IBS patients,
the applied long-lasting dough fermentation method, leading to a
potential degradation of 90% of the fructans and raffinose (a trisac-
charide that is the second most abundant FODMAP in wheat)
in modern and ancient wheat species appears to be substantially
more important than the selection of a specific wheat type.
Wheat and Mental-Psychological Disorders
Apart from the disorders mentioned above, effects on gut–brain
axis mediated mental–psychological disorders and well-being have
also been proposed (Hadjivassiliou et al., 2010). Although pro-
posed adverse effects of wheat or gluten on the brain and its
functions are beyond the scope of this review on intestinal re-
lated adverse reactions and disorders, it should be emphasized that
intestinal events can induce effects on the central nervous sys-
tem by means of the gut–brain axis (Oriach et al., 2016; Vitetta,
Vitetta, & Hall, 2018). For this reason, we present some back-
grounds here while referring to selected important papers. The
term “follow your gut feeling,” when making decisions, appears
to have a physiological basis by means of bidirectional commu-
nication pathways between gut and brain, in which gut micro-
biota, the hypothalamic–pituitary–adrenal (HPA) axis, and sero-
tonin metabolism play an important role. There are various lines
of growing evidence that the composition of gut microbiota and
related metabolism have impacts on brain metabolism and func-
tion, including cognition, behavior, mood, and mental disorders
(Allen, Dinan, Clarke, & Cryan, 2017; Kennedy, Cryan, Dinan,
& Clarke, 2017). Recently, Mu, Yang, and Zhu (2016) describes
gut microbiota as a ‘peace keeper’ in brain health. There are some
common neurotransmitter and metabolic pathways that play a role
in these disorders (Kennedy et al., 2017), which also can be in-
fluenced by diet (Julio-Pieper, Bravo, Aliaga, & Gotteland, 2014).
A possible role of gluten and/or wheat has been proposed, based
on several single case observations that alleviation of mental dis-
orders can take place after moving to a gluten-free diet (Lionetti,
Leonardi, et al., 2015). It has also been reported that consuming
wheat and/or gluten is associated with a variety of psychological
symptoms in children, such as depression and attentional problems
and that mothers who are unaware of their child having CD more
often report depression and anxiety, aggression, and sleep prob-
lems (Smith et al., 2017). An important question in this respect
is whether gluten, in addition to triggering CD, also the cause of
these problems or whether these are simply a comorbidity of CD.
Along similar lines, changes in intestinal microbiota composition
and activity have been associated with CD, pointing to a possible
role of microbiota in its etiology. However, there are at present nei-
ther studies demonstrating causality (Galipeau & Verdu, 2014), nor
address cause or consequence. For example, autism spectrum dis-
order is known be associated with a high prevalence of both eating
problems and gastrointestinal disorders. In children, eating/feeding
problems are complex and multifactorial (Chaidez et al., 2014) and
in many cases, it can be expected that the related eating disorders
themselves impact on nutrient supply and the gut microbiome,
rather than these being the cause of the disorders. Thus, many
suggestions that gluten or wheat is a direct cause of mental dis-
orders lack a sound evidence base with respect to components,
mechanisms, and cause—effect interactions. In addition, many
of the behavioral studies in this field are poorly controlled, have
small participant numbers andmade use of non-validated question-
naires (Holingue, Newill, Lee, Pasricha, & Daniele Fallin, 2018;
van De Sande, van Buul, & Brouns, 2014). Nevertheless, stud-
ies using microbe-free animal models, using fecal transplantation
and/or studies in which antibiotics-induced microbiota deple-
tion has been carried out, show metabolic and related behavioral
changes (Johnson & Foster, 2018). It is thought that such changes
are modulated bymicrobiota-associated metabolites, which in turn
strongly depend on the available substrates that enter the distal part
of the small intestine and subsequently the colon, where most mi-
crobial metabolism takes place. According to these observations,
the modulation of the microbiota by means of ingestion of pro-
and prebiotics that induce favorable effects on mental functions
(psychobiotics) has recently been proposed (Sarkar et al., 2016).
Recent work in pigs using distal-ileal-antibiotics infusion showed
altered neurotransmitter expression occurring simultaneously with
changes in both the large intestinal microbiota and the concentra-
tion of aromatic amino acids in the colon, blood, and hypothala-
mus (Gao et al., 2018). According to the researchers, these findings
indirectly indicate that intestinal microbiota can affect hypothala-
mic neurotransmitter expression, which in turn may impact on
brain function. These findings point to possible mechanisms and
interactions that remain to be shown to play a role in humans. In
fact, in humans, so many factors are involved in the day-to-day
changes in gut microbiota, their metabolism, and gut barrier func-
tion, including alcohol, infection, antibiotics, painkillers, stress,
and many dietary components (Rybnikova, 2018; Sandhu et al.,
2017), that conclusions about gluten or bread as a causal factor for
brain disorders cannot be drawn (Kelly, Clarke, Cryan, & Dinan,
2016). Clearly there is a need for well-controlled studies in this
respect (Fasano, 2017; Li & Zhou, 2016).
Conclusions
The prevalence of diagnosed celiac disease and wheat allergy as
well as self-perceived sensitivity to wheat and/or gluten appears
to be increasing over time. The term non-celiac gluten sensitivity
implies that, in the absence of celiac disease, gluten is the cause
of the reported symptoms. However, in addition to gluten, other
components present in wheat can potentially contribute to the
observed symptoms in these individuals. In this respect, there
has been a strong focus on rapidly fermentable carbohydrates
(FODMAP), leading some groups to conclude that not gluten but
FODMAP cause the sensitivity symptoms. In turn, this has lead to
changing the name from NCGS to non-celiac wheat sensitivity.
There is a significant overlap between the symptomatology of
individuals suffering from NCWS, CD, and IBS. In addition, IBS
and NCWS are both asssociated with high level of psychiatric
comorbidities. Many individuals suffering from self-perceived
NCWS claim that they benefit from eating ancient tetraploid
grains or spelt-wheat products instead of bread-wheat products.
However, these are closely related forms of the same hexaploid
species (Triticum aestivum) and contain gluten as well as ATIs and
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FODMAPs. Thus, at present, the widely promoted suggestion
that ancient grains are preferable for gluten sensitive individuals,
compared to modern hexaploid bread wheat, remains unproven.
It may be that social media news and related nocebo effects may
play a strong role in these perceptions. At present, systematical
unraveling of the possible pathophysiology caused by a variety
of components present in a variety of wheat types may provide
further insights into the mechanisms of wheat-related disorders
especially in NCWS. In addition, detailed characterization and
quantitative analysis of grain components,based on the availability
high quality standards materials, is required to underpin the
elimination of undesired components, either by food processing
or by targeted breeding including gene editing.
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